Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
19 11 2019
Historique:
received: 07 09 2019
accepted: 11 09 2019
pubmed: 23 9 2019
medline: 23 6 2020
entrez: 23 9 2019
Statut: ppublish

Résumé

Calcineurin Inhibitors (CNIs) are routinely used for immunosuppression following solid organ transplantation. However, the prolonged use of these agents lead to organ fibrosis which limits their efficacy. CNIs induce TGFβ expression, which is reported to augment endothelial-to-mesenchymal transition (EndMT), but their role in this process is not known. In these studies, we find that the CNIs FK506 and cyclosporine (CsA) are potent to increase endothelial cell (EC) proliferation using established in vitro assays (P < 0.05). Furthermore, using phosphokinase arrays, we find that each CNI activates the MAPK and Akt/mTOR signaling pathways, and that pharmacological inhibition of each pathway targets CNI-induced proliferative responses (P < 0.001). EndMT was evaluated by FACS for N-cadherin and CD31 expression and by qPCR for the expression of α-smooth muscle actin, N-cadherin and Snail. We find that CNIs do not directly induce dedifferentiation, while TGFβ and hypoxia induce EndMT in small numbers of EC. In contrast, the treatment of EC with the inflammatory cytokine TNFα was potent to elicit an EndMT response, and its effects were most notably in EC following proliferation/doubling. Taken together, these observations suggest that CNIs elicit proliferative responses, which enhance EndMT in association with local inflammation. The clinical implications of these findings are that anti-proliferative therapeutics have high potential to target the initiation of this EndMT response.

Identifiants

pubmed: 31542230
pii: S0006-291X(19)31764-4
doi: 10.1016/j.bbrc.2019.09.043
pmc: PMC7119266
mid: NIHMS1543117
pii:
doi:

Substances chimiques

Cadherins 0
Calcineurin Inhibitors 0
Tumor Necrosis Factor-alpha 0
Cyclosporine 83HN0GTJ6D
Tacrolimus WM0HAQ4WNM

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-673

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI092305
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007726
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Nat Med. 2010 Dec;16(12):1400-6
pubmed: 21102460
Front Immunol. 2012 Apr 02;3:54
pubmed: 22566935
Transplantation. 2007 Jun 27;83(12):1542-50
pubmed: 17589335
Ann Transplant. 2016 Dec 20;21:775-783
pubmed: 27994216
J Immunol. 1979 Aug;123(2):751-4
pubmed: 37274
Am J Transplant. 2011 Apr;11(4):693-7
pubmed: 21446974
Immunobiology. 2013 Apr;218(4):443-54
pubmed: 22739237
Am J Transplant. 2019 Sep;19(9):2434-2445
pubmed: 30836425
Nat Med. 2007 Aug;13(8):952-61
pubmed: 17660828
J Pathol. 2016 Feb;238(3):378-80
pubmed: 26446982
Circ Res. 2010 Aug 6;107(3):418-28
pubmed: 20522804
J Cell Sci. 1992 Oct;103 ( Pt 2):521-9
pubmed: 1478952
J Biol Chem. 2010 Aug 13;285(33):25196-202
pubmed: 20554520
Curr Opin Nephrol Hypertens. 2011 May;20(3):297-305
pubmed: 21422927
J Am Soc Nephrol. 2011 Jun;22(6):1024-9
pubmed: 21566051
J Am Coll Cardiol. 2019 Jan 22;73(2):190-209
pubmed: 30654892
Kidney Int. 1996 May;49(5):1297-303
pubmed: 8731094
FEBS Lett. 1995 Jan 23;358(2):109-12
pubmed: 7828718
Am J Pathol. 2011 Nov;179(5):2660-73
pubmed: 21945322
Nat Med. 2002 Feb;8(2):128-35
pubmed: 11821896
J Clin Invest. 2007 Dec;117(12):3774-85
pubmed: 18060031
J Cell Biol. 1974 Mar;60(3):673-84
pubmed: 4363161
Biochem J. 2011 Aug 1;437(3):515-20
pubmed: 21585337
J Am Soc Nephrol. 2016 Jan;27(1):324-32
pubmed: 25995444
Nephrol Dial Transplant. 2014 Apr;29(4):799-808
pubmed: 24463188
Am J Pathol. 2010 Jan;176(1):85-97
pubmed: 20008127
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 2008 Oct 3;283(40):27230-8
pubmed: 18660502
J Clin Invest. 2003 Dec;112(11):1655-65
pubmed: 14660742
Ann N Y Acad Sci. 2005 Jun;1051:551-8
pubmed: 16126995

Auteurs

Craig B Woda (CB)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

Sarah Bruneau (S)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

Anne Linde Mak (AL)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

Zdenka Haskova (Z)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

Kaifeng Liu (K)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA.

Chandra C Ghosh (CC)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

David M Briscoe (DM)

The Transplant Research Program and the Division of Nephrology, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: David.Briscoe@childrens.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH